Skip to main
LGND

Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target

Ligand Pharmaceuticals (LGND) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ligand Pharmaceuticals is positioned for future success due to its strong portfolio of royalty-generating assets and commitment to sustainability, as evidenced by reaffirming its revenue and earnings guidance and recent acquisition of XOMA. With the recent approval of FILSPARI, the company is expected to see continued revenue growth and has a raised valuation. While there are risks related to revenue sources and acquisitions, the company is taking proactive steps by engaging shareholders and employees in 2024.

Bears say

Ligand Pharmaceuticals is a biopharmaceutical company that relies heavily on partnerships and license agreements for revenue. However, the company faces risks such as the potential for competition, underperformance of pipeline drugs, and value-destructive deals. These factors, combined with the uncertainty surrounding the outcome of ongoing litigation and the acquisition of XOMA, contribute to a negative outlook on the company's stock.

Ligand Pharmaceuticals (LGND) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ligand Pharmaceuticals (LGND) Forecast

Analysts have given Ligand Pharmaceuticals (LGND) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Ligand Pharmaceuticals (LGND) has a Strong Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $257.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $257.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ligand Pharmaceuticals (LGND)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.